These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1472 related items for PubMed ID: 23146246

  • 1. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

  • 2. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 4. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME.
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
    Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME.
    J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
    [Abstract] [Full Text] [Related]

  • 6. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 7. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K, Andersen HF, Reines EH.
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [Abstract] [Full Text] [Related]

  • 8. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
    Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG.
    Depress Anxiety; 2010 May; 27(5):417-25. PubMed ID: 20455246
    [Abstract] [Full Text] [Related]

  • 9. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
    McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH, EMBOLDEN II (Trial D1447C00134) Investigators.
    J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S, Desaiah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD.
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [Abstract] [Full Text] [Related]

  • 11. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME.
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A.
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [Abstract] [Full Text] [Related]

  • 13. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

  • 14. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [Abstract] [Full Text] [Related]

  • 15. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, Thompson PM, Shelton RC.
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [Abstract] [Full Text] [Related]

  • 16. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [Abstract] [Full Text] [Related]

  • 17. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
    Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M, EMBOLDEN I (Trial 001) Investigators.
    J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369
    [Abstract] [Full Text] [Related]

  • 18. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P, Lönn SL, Overø KF.
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [Abstract] [Full Text] [Related]

  • 19. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A, Korotzer A, Gommoll C, Li D.
    Depress Anxiety; 2008 Feb; 25(10):854-61. PubMed ID: 18050245
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M.
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.